Exendin-4 for Parkinson's disease

Felipe de Jesús Esparza-Salazar; Alma Rosa Lezama-Toledo; Germán Rivera-Monroy; Cesario V Borlongan

doi:10.4103/bc.bc_21_21

Exendin-4 for Parkinson's disease

Brain Circ. 2021 Mar 30;7(1):41-43. doi: 10.4103/bc.bc_21_21. eCollection 2021 Jan-Mar.

Authors

Felipe de Jesús Esparza-Salazar¹, Alma Rosa Lezama-Toledo¹, Germán Rivera-Monroy¹, Cesario V Borlongan¹

Affiliation

¹ Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

Abstract

This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.

Keywords: Exenatide; Parkinson's disease; exendin-4; glucagon-like peptide-1.

Publication types

Review